Tilray Stock Has Crashed 90%. Could Marijuana Rescheduling Spark a Massive Comeback?

Tilray's shares are still down more than 90% over five years, and the article argues the U.S. cannabis rescheduling shift is unlikely to create a sustained rally. While moving FDA-approved marijuana products and certain medical cannabis products from Schedule I to Schedule III could ease research and allow some tax deductions, recreational cannabis remains excluded and federal legalization is still absent. Tilray remains unprofitable with inconsistent revenue growth, and the piece warns that competition and structural barriers continue to limit the stock's long-term appeal.

Analysis

The market is likely to misread this as a near-term catalyst for cannabis equities when it is really a slow-burn regulatory de-risking. The first-order benefit is to balance-sheet quality: if Schedule III treatment improves tax deductibility and research access, the winners are the companies with enough liquidity to survive long enough to harvest those savings. That makes this more of a survival filter than a re-rating catalyst for legacy growers with weak unit economics.

TLRY’s problem is that its equity is still trading like an option on broad federal legalization, but the operating business is being forced to compete in a structurally inefficient distribution model while also carrying non-cannabis assets that dilute the pure-play upside. If federal reform stays partial, larger consumer staples, alcohol, and pharma players are unlikely to enter aggressively; if reform becomes broader, they are exactly the competitors most likely to compress margins and overwhelm weak brands. In that sense, improved legality can actually sharpen competition before it improves profitability.

The setup is bearish on a 3-12 month horizon because the stock needs multiple sequential catalysts: further rescheduling, cash-flow improvement, and evidence that Tilray has a defensible channel position. Absent that, the likely path is repeated short-lived spikes on headlines followed by dilution/earnings gravity. The cleaner expression is that policy progress reduces bankruptcy odds for the sector, but not necessarily equity value for the weakest operators.

The contrarian angle is that the move may still be underpriced for adjacent beneficiaries that can monetize CBD/hemp, wellness distribution, or tax savings without relying on THC legalization. The market is focusing on headline cannabis beta, but the real second-order trade may be in firms with optionality on regulated consumer health products and lower regulatory burn rates. For TLRY specifically, the asymmetry remains poor unless it can show operating leverage before the next policy headline fades.

Key Decisions for Investors

• Stay short TLRY on headline-driven strength; use 1-3 week rallies after policy news to add exposure, with a hard stop above the prior post-news high because the stock remains a squeeze candidate.
• Prefer a pair trade: long a profitable alcohol or consumer staple name with M&A/portfolio optionality, short TLRY for 3-6 months; the thesis is that regulatory progress benefits incumbents with balance-sheet strength more than distressed growers.
• Avoid outright long cannabis beta until there is evidence of sustained cash-flow inflection; if you want policy upside, wait for a quarterly print showing margin expansion rather than buying the headline.
• For event-driven traders, consider a small long-dated call spread only if broader federal rescheduling becomes imminent; otherwise the theta burn is unfavorable because the catalyst path is too slow and too binary.
• Watch for dilution risk over the next 6-12 months; if capital markets reopen for TLRY at elevated prices, use that as a signal that the market is temporarily over-enthusiastic and fade the move.